Quick Navigation

Menopause

Menopause is the stage of life when menses permanently cease, and the reproductive system no longer performs functions related to fertility. A woman is considered to have entered menopause after menses have stopped for 12 months.

Our evidence-based analysis on menopause features 114 unique references to scientific papers.

Research analysis led by and reviewed by the Examine team.
Last Updated:

Research Breakdown on Menopause


1At what age does menopause typically start?

Natural menopause generally occurs in women at around 51 years of age with no pathological or physiological cause, but early menopause can result from surgery, chemotherapy, radiotherapy, or primary ovarian insufficiency. Perimenopause is the transitional phase into menopause and may last between 4 to 8 years.[2]

2Are there recommendations for women who started menopause early?

Young women with primary ovarian insufficiency (POI) experience symptoms similar to menopause. For women with POI and no contraindications (like breast cancer), the American College of Obstetricians and Gynecologists recommends hormone replacement therapy. This includes the use of prescription estrogen therapy until around age 50 to reduce the risk of osteoporosis, cardiovascular disease, and urogenital atrophy. Some women may require vaginal estrogen in addition to systemic estrogen. Young women with POI should have an annual thyroid exam as they are at increased risk of developing Hashimoto's thyroiditis.[38] 

In addition to medical management, women with POI may find the following lifestyle interventions helpful: eat a diet rich in calcium, maintain adequate vitamin D levels, perform weight-bearing exercises, limit caffeine and alcohol intake, and avoid smoking.[39]

3What are the main symptoms of menopause?

During perimenopause and sometimes even postmenopause, women can experience symptoms like hot flashes, night sweats, vaginal dryness, insomnia, trouble focusing, and mood swings. Women may also notice changes in body composition, such as reduced lean mass and increased fat mass, particularly around the abdomen. The majority of these symptoms are a result of hormonal fluctuations, with hot flashes among the most commonly reported.[2] 

4What are hot flashes, when do they occur, and how long do they last?

Vasomotor symptoms (VMS), more commonly known as hot flashes and night sweats, affect roughly 80% of women in their late-forties to mid-fifties. They often begin in perimenopause and peak in the later perimenopause and early postmenopausal years. Hot flashes present as a feeling of intense heat, resulting in sweating and flushing, predominantly around the head, neck, chest, and upper back. The physiology of hot flashes is not fully known, but they are presumed to be linked to low estrogen and elevated luteinizing hormone.[40]

Not all menopausal women experience hot flashes, so there may be other biological mechanisms at play. Some evidence points to a narrowing of the thermal neutral zone during menopause, meaning slight temperature fluctuations can trigger thermoregulatory processes that dissipate heat, resulting in flushing and sweating.[41] 

5How does menopause affect urogenital tissue?

Genitourinary syndrome of menopause (GSM), or vaginal atrophy, results from a loss of estrogen. GSM results in a variety of adverse consequences like vaginal dryness, burning, increased urinary frequency, and recurring bladder infections. For many women, this condition requires long-term management. For moderate to severe cases of GSM, low-dose vaginal estrogen is regarded as the most effective treatment, and for mild cases, non-hormonal topical lubricants are recommended.[42] 

6What are some other conditions that are associated with menopause?

The following are some other conditions that commonly occur during menopause:
-Perimenopausal women are 2 to 4 times more likely to suffer from depression, and some women have reported increased episodes of forgetfulness during this time.
-The risk of developing heart disease increases with age, and it increases even more in women after menopause due to declining estrogen and increased blood pressure, LDL-cholesterol, and triglycerides.
-Osteoporosis risk increases in menopause. Bone loss occurs in two phases: the first phase occurs in perimenopause, as bone resorption increases due to estrogen deficiency; the second phase occurs 4 to 8 years after the menopausal transition, when bone formation slows.[2]

References

  1. ^ Henry G Burger, et al. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause. (Jul-Aug)
  2. ^ a b c d Kimberly Peacock, Kari M. Ketvertis. Menopause.
  3. ^ Shannon D Sullivan, Philip M Sarrel, Lawrence M Nelson. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. (2016)
  4. ^ Danielle A J M Schoenaker, et al. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. (2014)
  5. ^ a b c Nanette Santoro, C Neill Epperson, Sarah B Mathews. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. (2015)
  6. ^ Rebecca C Thurston, Hadine Joffe. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. (2011)
  7. ^ Kimberley Thornton, Judi Chervenak, Genevieve Neal-Perry. Menopause and Sexuality. Endocrinol Metab Clin North Am. (2015)
  8. ^ A M Calafiore, et al. Blood platelet count and bubble oxygenators. Changes induced by the oral administration of dipyridamole. Minerva Cardioangiol. (1989)
  9. ^ Gail A Greendale, et al. Changes in body composition and weight during the menopause transition. JCI Insight. (2019)
  10. ^ Agnieszka Dmitruk, et al. Body composition and fatty tissue distribution in women with various menstrual status. Rocz Panstw Zakl Hig. (2018)
  11. ^ S M McKinlay, D J Brambilla, J G Posner. The normal menopause transition. Maturitas. (1992)
  12. ^ Zenab Amin, Turhan Canli, C Neill Epperson. Effect of estrogen-serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev. (2005)
  13. ^ G A Greendale, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. (2009)
  14. ^ George Wells, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. (2002)
  15. ^ Guo-Qiang Zhang, et al. Menopausal hormone therapy and women's health: An umbrella review. PLoS Med. (2021)
  16. ^ Kathryn Ann Martin, Joann E Manson. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab. (2008)
  17. ^ James W Daily, et al. Equol Decreases Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Med Food. (2019)
  18. ^ Pang Yao, et al. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open. (2019)
  19. ^ L C Swartzman, R Edelberg, E Kemmann. Impact of stress on objectively recorded menopausal hot flushes and on flush report bias. Health Psychol. (1990)
  20. ^ C M van Driel, et al. Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. BJOG. (2019)
  21. ^ Hye Won Lee, et al. Aromatherapy for Managing Menopausal Symptoms: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. J Altern Complement Med. (2021)
  22. ^ Fatemeh Darsareh, et al. Effect of aromatherapy massage on menopausal symptoms: a randomized placebo-controlled clinical trial. Menopause. (2012)
  23. ^ Fei-Yi Zhao, et al. Comparative Utility of Acupuncture and Western Medication in the Management of Perimenopausal Insomnia: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. (2021)
  24. ^ Hsiao-Yean Chiu, et al. Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis of randomized controlled trials. Menopause. (2015)
  25. ^ a b Karen M Goldstein, et al. Nonpharmacologic Treatments for Menopause-Associated Vasomotor Symptoms Internet.
  26. ^ Tsai-Ju Chien, et al. Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis. PLoS One. (2017)
  27. ^ M Shepherd-Banigan, et al. Improving vasomotor symptoms; psychological symptoms; and health-related quality of life in peri- or post-menopausal women through yoga: An umbrella systematic review and meta-analysis. Complement Ther Med. (2017)
  28. ^ Renqing Zhao, Mengyi Zhang, Qi Zhang. The Effectiveness of Combined Exercise Interventions for Preventing Postmenopausal Bone Loss: A Systematic Review and Meta-analysis. J Orthop Sports Phys Ther. (2017)
  29. ^ M Martyn-St James, S Carroll. A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes. Br J Sports Med. (2009)
  30. ^ Traci A Takahashi, Kay M Johnson. Menopause. Med Clin North Am. (2015)
  31. ^ . The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. (2020)
  32. ^ Swati Jha, Lynda Wyld, Priyanka H Krishnaswamy. The Impact of Vaginal Laser Treatment for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review and Meta-analysis. Clin Breast Cancer. (2019)
  33. ^ Eleni Pitsouni, et al. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. (2017)
  34. ^ Masoud Isanejad, et al. Dietary protein intake is associated with better physical function and muscle strength among elderly women. Br J Nutr. (2016)
  35. ^ Xingqiong Meng, et al. A 5-year cohort study of the effects of high protein intake on lean mass and BMC in elderly postmenopausal women. J Bone Miner Res. (2009)
  36. ^ Radhika N Bukkapatnam, et al. Postprandial metabolic responses to dietary glycemic index in hypercholesterolemic postmenopausal women. Prev Cardiol. (Winter)
  37. ^ Seong-Hee Ko, Hyun-Sook Kim. Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women. Nutrients. (2020)
  38. ^ . Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol. (2017)
  39. ^ Rose Marino, Madhusmita Misra. Bone health in primary ovarian insufficiency. Semin Reprod Med. (2011)
  40. ^ Lara Delamater, Nanette Santoro. Management of the Perimenopause. Clin Obstet Gynecol. (2018)
  41. ^ Ramandeep Bansal, Neelam Aggarwal. Menopausal Hot Flashes: A Concise Review. J Midlife Health. (Jan-Mar)
  42. ^ Jason Gandhi, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. (2016)
  43. Lee GA, et al. Archaeological soybean (Glycine max) in East Asia: does size matter?. PLoS One. (2011)
  44. Barnes S. The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol. (2010)
  45. Lusas EW, Riaz MN. Soy protein products: processing and use. J Nutr. (1995)
  46. Liener IE. Implications of antinutritional components in soybean foods. Crit Rev Food Sci Nutr. (1994)
  47. Egounlety M, Aworh OC. Effect of soaking, dehulling, cooking and fermentation with Rhizopus oligosporus on the oligosaccharides, trypsin inhibitor, phytic acid and tannins of soybean (Glycine max Merr.), cowpea (Vigna unguiculata L. Walp) and groundbean (Macrotyloma geocarpa Harms). Journal of Food Engineering. (2003)
  48. el-Adawy TA, et al. Effect of soaking process on nutritional quality and protein solubility of some legume seeds. Nahrung. (2000)
  49. Miyagi Y, et al. Trypsin inhibitor activity in commercial soybean products in Japan. J Nutr Sci Vitaminol (Tokyo). (1997)
  50. Adeyemo SM, Onilude AA. Enzymatic Reduction of Anti-nutritional Factors in Fermenting Soybeans by Lactobacillus plantarum Isolates from Fermenting Cereals. Nigerian Food Journal. (2013)
  51. Anderson RL, Wolf WJ. Compositional changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to soybean processing. J Nutr. (1995)
  52. Zaheer K, Humayoun Akhtar M. An updated review of dietary isoflavones: Nutrition, processing, bioavailability and impacts on human health. Crit Rev Food Sci Nutr. (2017)
  53. Lu Z, et al. S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway. Curr Cancer Drug Targets. (2016)
  54. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. (2002)
  55. Shor D, et al. Does equol production determine soy endocrine effects?. Eur J Nutr. (2012)
  56. Birru RL, et al. The impact of equol-producing status in modifying the effect of soya isoflavones on risk factors for CHD: a systematic review of randomised controlled trials. J Nutr Sci. (2016)
  57. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer. (2006)
  58. Zamora-Ros R, et al. Dietary intakes and food sources of phytoestrogens in the European Prospective Investigation into Cancer and Nutrition (EPIC) 24-hour dietary recall cohort. Eur J Clin Nutr. (2012)
  59. Setchell KD, Cole SJ. Variations in isoflavone levels in soy foods and soy protein isolates and issues related to isoflavone databases and food labeling. J Agric Food Chem. (2003)
  60. Golbitz P. Traditional soyfoods: processing and products. J Nutr. (1995)
  61. Doerge DR, Chang HC. Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. J Chromatogr B Analyt Technol Biomed Life Sci. (2002)
  62. Divi RL, Chang HC, Doerge DR. Anti-thyroid isoflavones from soybean: isolation, characterization, and mechanisms of action. Biochem Pharmacol. (1997)
  63. Messina M, Redmond G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid. (2006)
  64. Bitto A, et al. Genistein aglycone does not affect thyroid function: results from a three-year, randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. (2010)
  65. Steinberg FM, et al. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr. (2011)
  66. Nakamura Y, et al. Soy isoflavones inducing overt hypothyroidism in a patient with chronic lymphocytic thyroiditis: a case report. J Med Case Rep. (2017)
  67. Bajaj JK, Salwan P, Salwan S. Various Possible Toxicants Involved in Thyroid Dysfunction: A Review. J Clin Diagn Res. (2016)
  68. Yan Z, et al. Association between consumption of soy and risk of cardiovascular disease: A meta-analysis of observational studies. Eur J Prev Cardiol. (2017)
  69. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. (1995)
  70. Erdman JW Jr. AHA Science Advisory: Soy protein and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation. (2000)
  71. Li SS, et al. Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. (2017)
  72. Jenkins DJ, et al. Soy protein reduces serum cholesterol by both intrinsic and food displacement mechanisms. J Nutr. (2010)
  73. Harland JI, Haffner TA. Systematic review, meta-analysis and regression of randomised controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis. (2008)
  74. Taku K, et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. (2007)
  75. Reynolds K, et al. A meta-analysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol. (2006)
  76. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. (2005)
  77. Sacks FM, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. (2006)
  78. Liu XX, et al. Effect of soy isoflavones on blood pressure: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. (2012)
  79. Dong JY, et al. Effect of soya protein on blood pressure: a meta-analysis of randomised controlled trials. Br J Nutr. (2011)
  80. Beavers DP, et al. Exposure to isoflavone-containing soy products and endothelial function: a Bayesian meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. (2012)
  81. Pase MP, Grima NA, Sarris J. The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. Am J Clin Nutr. (2011)
  82. Bae M, et al. Inhibitory effects of isoflavonoids on rat prostate testosterone 5α-reductase. J Acupunct Meridian Stud. (2012)
  83. Hamilton-Reeves JM, et al. Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis. Fertil Steril. (2010)
  84. Kalman D, et al. Effect of protein source and resistance training on body composition and sex hormones. J Int Soc Sports Nutr. (2007)
  85. Beaton LK, et al. Soy protein isolates of varying isoflavone content do not adversely affect semen quality in healthy young men. Fertil Steril. (2010)
  86. Mitchell JH, et al. Effect of a phytoestrogen food supplement on reproductive health in normal males. Clin Sci (Lond). (2001)
  87. Martinez J, Lewi JE. An unusual case of gynecomastia associated with soy product consumption. Endocr Pract. (2008)
  88. Siepmann T, et al. Hypogonadism and erectile dysfunction associated with soy product consumption. Nutrition. (2011)
  89. Applegate CC, et al. Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis. Nutrients. (2018)
  90. van Die MD, et al. Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int. (2014)
  91. Miyanaga N, et al. Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci. (2012)
  92. Hamilton-Reeves JM, et al. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer. (2008)
  93. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. (2015)
  94. Hooper L, et al. Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis. Hum Reprod Update. (2009)
  95. Key T, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. (2002)
  96. Hooper L, et al. Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum Reprod Update. (2010)
  97. Chen M, et al. Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies. PLoS One. (2014)
  98. Ziaei S, Halaby R. Dietary Isoflavones and Breast Cancer Risk. Medicines (Basel). (2017)
  99. Chi F, et al. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. (2013)
  100. Nechuta SJ, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. (2012)
  101. Taku K, et al. Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. (2010)
  102. Liu J, et al. Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. Bone. (2009)
  103. Taku K, et al. Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone. (2010)
  104. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric. (2015)
  105. Taku K, et al. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. (2012)
  106. Vanegas JC, et al. Soy food intake and treatment outcomes of women undergoing assisted reproductive technology. Fertil Steril. (2015)
  107. Jacobsen BK, et al. Soy isoflavone intake and the likelihood of ever becoming a mother: the Adventist Health Study-2. Int J Womens Health. (2014)
  108. McCarver G, et al. NTP-CERHR expert panel report on the developmental toxicity of soy infant formula. Birth Defects Res B Dev Reprod Toxicol. (2011)
  109. Adgent MA, et al. A Longitudinal Study of Estrogen-Responsive Tissues and Hormone Concentrations in Infants Fed Soy Formula. J Clin Endocrinol Metab. (2018)
  110. Harlid S, et al. Soy Formula and Epigenetic Modifications: Analysis of Vaginal Epithelial Cells from Infant Girls in the IFED Study. Environ Health Perspect. (2017)
  111. Tuohy PG. Soy infant formula and phytoestrogens. J Paediatr Child Health. (2003)
  112. Jefferson WN, Williams CJ. Circulating levels of genistein in the neonate, apart from dose and route, predict future adverse female reproductive outcomes. Reprod Toxicol. (2011)
  113. Kim SH, Park MJ. Effects of phytoestrogen on sexual development. Korean J Pediatr. (2012)
  114. Jefferson WN, Patisaul HB, Williams CJ. Reproductive consequences of developmental phytoestrogen exposure. Reproduction. (2012)